Neumora Therapeutics (NMRA) Long-Term Debt Issuances (2025)
Neumora Therapeutics (NMRA) posted quarterly Long-Term Debt Issuances of $38.9 million for Q4 2025, up 28702.21% quarter-over-quarter from -$136000.0 in Q3 2025.
Powered by 
Analysis
Neumora Therapeutics (NMRA) Long-Term Debt Issuances (2025) Analysis & Trends
Neumora Therapeutics' Long-Term Debt Issuances history runs 1 years deep, the most recent figure standing at $38.9 million for Q4 2025.
- In Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to $38.9 million; the TTM figure through Dec 2025 stood at $38.8 million (changed N/A YoY), while the FY2025 annual figure was $57.2 million, changed N/A from the prior year.
- Long-Term Debt Issuances for Q4 2025 stood at $38.9 million, up from -$136000.0 in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $38.9 million in Q4 2025, with the low at -$136000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | - |
| 10 | Neumora Therapeutics | 243.49 Mn | 243.49 Mn | - | - |